Neurology News

Biopharmaceutical company AbbVie has submitted a new drug application to the FDA for ABBV-951, a 24-hour subcutaneous treatment for motor fluctuations in patients with advanced Parkinson's disease.

May is Brain Cancer Awareness Month.

SAN DIEGO — Minimal long-term cardiac safety findings were reported with ozanimod treatment in patients with ulcerative colitis and relapsing multiple sclerosis, according to research presented at Digestive Disease Week 2022.

Patients with young-onset dementia are at greater risk for hospitalization due to motor vehicle crash injury than those without dementia, according to a study published in JAMA Network Open.

The introduction of a multifaceted educational campaign was associated with significant improvements in ambulance use and hospital arrival times for patients with stroke, according to a study published in JAMA Network Open.

Relapsing MS patients, as well as those with disability progression independent of relapse activity, experienced increased brain atrophy, specifically in the cerebral cortex, researchers reported in JAMA Neurology.

Cumulative cardiovascular risk is a significant factor in determining the risk for cognitive decline and dementia, according to a study published in Neurology.

An intervention significantly decreased the rate of potentially inappropriate prescribing among older adults in an ED setting, according to findings from a recent study.

In this week’s edition, childhood sexual and emotional abuse increases the risk for multiple sclerosis in women; fentanyl-related cardiac arrest is linked to worse neurological outcomes; Black patients with MS have a higher rate of disability compared with their white counterparts; and more.

In patients with moderate or severe ischemic stroke, a lower dose of IV tenecteplase yielded less favorable functional outcomes compared to a higher standard dose of alteplase, according to data published in The Lancet Neurology.